References
- de Koning Gans JM, Uiterwaal CS, van der Schouw YT, et al Tea and coffee consumption and cardiovascular morbidity and mortality. Arterioscler Thromb Vasc Biol 2010;30:1665–71
- Wu JN, Ho SC, Zhou C, et al Coffee consumption and risk of coronary heart diseases: A meta-analysis of 21 prospective cohort studies. Int J Cardiol 2009;137:216–25
- Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, et al Coffee consumption and risk of stroke in women. Circulation 2009; 119:1116–23
- Andersen LF, Jacobs DR Jr, Carlsen MH, Blomhoff R. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women's Health Study. Am J Clin Nutr 2006;83: 1039–46
- Lopez-Garcia E, van Dam RM, Li TY, et al The relationship of coffee consumption with mortality. Ann Intern Med 2008; 148:904–14
- Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001;154:495–503
- Kuriyama S, Shimazu T, Ohmori K, et al Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006;296:1255–65
- Arts IC, Jacobs DR Jr, Harnack LJ, et al Dietary catechins in relation to coronary heart disease death among postmenopausal women. Epidemiology 2001;12:668–75
- Geleijnse JM, Launer LJ, Van der Kuip DA, et al Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr 2002;75: 880–6
- Hertog MG, Feskens EJ, Hollman PC, et al Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007–11
References
- Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010;363:1203–10
- Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008;168:2311–16
- Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of overdiagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 2006;332:689–92
- Jorgensen KJ, Gotzche PC. Overdiagnosis in publicly organized mammography screening programmers: systematic review of incidence trends. BMJ 2009;339:b2587
- Santen RJ, Allred DC, Ardoin SP, et al Postmenopausal hormone therapy: an Endocrine Society Supplement: J Clin Endocrinol Metab 2010;95(Suppl 1):S1–66
References
- Olivo-Marston SE, Mechanic LE, Mollerup S, et al Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis 2010;31:1778–86
- Egleston BL, Meireles SI, Flieder DB, Clapper ML. Population-based trends in lung cancer incidence in women. Semin Oncol 2009;36:506–15
- Raso MG, Behrens C, Herynk MH, et al Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009;15:5359–68
- Chlebowski RT, Schwartz AG, Wakelee H. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243–51
- Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int J Epidemiol 2003;32:263–71
- Schabath MB, Wu X, Vassilopoulou-Sellin R, et al Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004;10:113–23
- Chen KY, Hsiao CF, Chang GC. Hormone replacement therapy and lung cancer risk in Chinese. Cancer 2007;110:1768–75
- Ramnath N, Menezes RJ, Loewen G, et al Hormone replace ment therapy as a risk factor for non-small cell lung cancer: Results of a case-control study. Oncology 2007;73:305–10
References
- Kanis JA, Johansson H, Oden A, et al A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010;47:729–35
- http://www.shef.ac.uk/FRAX
- Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care levelUKWHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield2007
- Kanis JA, Johnell O, Oden A, et al FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385–97
- Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44:1049–54
- McCloskey EV, Johansson H, Oden A, et al Ten-year fracture probability identifies women who will benefit from clodronate therapy – additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009;20:811–17
- Ettinger B, Black DM, Mitlak BH, et al Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45
References
- De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 2010;102:1489–95
- Rossouw JE, Anderson GL, Prentice RL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 2007;9:R28
- Ravdin PM, Cronin KA, Howlander N, et al A sharp decrease in breast cancer incidence in the United States in 2003, abstract. Paper presented at 29th Annual San Antonio Breast Cancer Symposium; Dec 14, 2006, Texas, USASan Antonio
- Ravdin PM, Cronin KA, Howlader N, et al The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–4
- Clarke CA, Glaser SL, Uratsu CS, et al Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:e49–50
- Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152–61